Parallel Advisors’s Standard BioTools LAB Stock Holding History

Parallel Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30	Hold	37	–	–	﹤0.01%	3902
2026 Q1	$34	Hold	37	–	–	﹤0.01%	3802
2025 Q4	$47	Hold	37	–	–	﹤0.01%	3574
2025 Q3	$48	Hold	37	–	–	﹤0.01%	3513
2025 Q2	$44	Hold	37	–	–	﹤0.01%	3498
2025 Q1	$40	Hold	37	–	–	﹤0.01%	3470
2024 Q4	$65	Hold	37	–	–	﹤0.01%	3468
2024 Q3	$71	Hold	37	–	–	﹤0.01%	3346
2024 Q2	$65	Sell	37 -5,953	-99%	-$14.6K	﹤0.01%	3262
2024 Q1	$16.2K	Buy	+5,990	New	+$14.5K	﹤0.01%	2092
2022 Q2	–	Sell	-6,895	Closed	-$26K	–	3186
2022 Q1	$26K	Hold	6,895	–	–	﹤0.01%	1600
2021 Q4	$27K	Hold	6,895	–	–	﹤0.01%	1638
2021 Q3	$45K	Hold	6,895	–	–	﹤0.01%	1324
2021 Q2	$42K	Hold	6,895	–	–	﹤0.01%	1329
2021 Q1	$31K	Hold	6,895	–	–	﹤0.01%	1396
2020 Q4	$41K	Hold	6,895	–	–	﹤0.01%	1182
2020 Q3	$51K	Sell	6,895 -3,676	-35%	-$25.4K	﹤0.01%	1062
2020 Q2	$42K	Hold	10,571	–	–	﹤0.01%	1112
2020 Q1	$26K	Buy	+10,571	New	+$34.7K	﹤0.01%	1197
2019 Q4	–	Sell	-1,727	Closed	-$8K	–	2452
2019 Q3	$8K	Buy	1,727 +651	+61%	+$5.13K	﹤0.01%	1758
2019 Q2	$13K	Buy	+1,076	New	+$13.7K	﹤0.01%	1471

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Parallel Advisors's LAB Position: Q2 2026 in Review

Parallel Advisors held its Standard BioTools (LAB) position steady in Q2 2026 at 37 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Parallel Advisors first reported a position in LAB in Q2 2019 and has held it in 21 quarters since. The position peaked at $51K in Q3 2020. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Parallel Advisors held 37 shares of Standard BioTools worth $30 as of Q2 2026.
Parallel Advisors left its Standard BioTools share count unchanged in Q2 2026.
Standard BioTools made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3902 holding.
Parallel Advisors first reported a position in Standard BioTools in Q2 2019 and has held it in 21 quarters since.
Parallel Advisors's Standard BioTools position peaked at $51K in Q3 2020.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.